Journal article
Recommendations for evaluating a single surrogate endpoint (REASSurE): consensus based, surrogate evaluation framework with explanation and elaboration
BMJ. British medical journal (Clinical research ed.), Vol.394, e100618
09/29/2026
DOI: 10.1136/bmj-2026-100618
PMCID: PMC13714761
PMID: 42810755
Abstract
The use of a surrogate endpoint to replace a primary outcome relevant to patients in a clinical trial may allow faster approval of a novel treatment, but at the cost of increased uncertainty about treatment benefit. This risk may be amplified if the surrogate endpoint was inadequately or inappropriately evaluated against the patient relevant outcome. Many components of this evaluation currently lack consensus, including the most important non-statistical factors, the choice of statistical method, and whether numerical thresholds should be used. This paper presents a consensus based, multi-stakeholder framework (REASSurE: Recommendations for Evaluating A Single Surrogate Endpoint) containing a list of mandatory and recommended items for surrogate endpoint evaluation, with guidance on how to assess each item. Statisticians, trials methodologists, regulators, health technology assessment agencies, payers, and clinicians could use the REASSurE framework to achieve a holistic evaluation of a candidate surrogate endpoint, which is vital to ensure that the use of the surrogate endpoint is an appropriate decision.
Details
- Title: Subtitle
- Recommendations for evaluating a single surrogate endpoint (REASSurE): consensus based, surrogate evaluation framework with explanation and elaboration
- Creators
- Wang Lo - Glasgow Centre for Population HealthStuart Baker - Independent SectorBertolaccini LucaBujkiewicz SylwiaBunce CateyMarc Buyse - International Drug Development Institute (Belgium)Ciani OrianaRobin Christensen - University of Southern DenmarkJane Daniels - University of NottinghamSara Gandini - European Institute of OncologyTamer Gheita - Cairo UniversityPeter Gilbert - Fred Hutch Cancer CenterLaura Jaeger - Center for Drug Evaluation and ResearchKareithi DorcasLassere MarissaNicholas Longford - SGH Warsaw School of EconomicsAnthony Manyara - University of BristolOba KojiEmily Roberts - University of IowaRod Taylor - University of GlasgowCarlos Toro-Huamanchumo - Universidad San Ignacio de LoyolaLewis SteffHannah Ensor - University of EdinburghChristopher Weir - University of Edinburgh
- Resource Type
- Journal article
- Publication Details
- BMJ. British medical journal (Clinical research ed.), Vol.394, e100618
- DOI
- 10.1136/bmj-2026-100618
- PMID
- 42810755
- PMCID
- PMC13714761
- NLM abbreviation
- BMJ
- ISSN
- 0959-535X
- eISSN
- 1756-1833
- Publisher
- BMJ Publishing Group LTD
- Grant note
- MRC-NIHR Trials Methodology Research - University of Edinburgh Foulkes Foundation fellowship - Medical Research Council: MR/T025166/1 Leicester NIHR Biomedical Research Centre Parker Institute Oak Foundation: OFIL-24-074
WPL was supported in this work by an MRC-NIHR Trials Methodology Research Partnership PhD studentship funded by the University of Edinburgh, and by a Foulkes Foundation fellowship. SB was funded by the Medical Research Council, methodology research grant (MR/T025166/1); SB received support from the Leicester NIHR Biomedical Research Centre. RC reports that the Section for Biostatistics and Evidence-Based Research, the Parker Institute, Bispebjerg and Frederiksberg Hospital is supported by a core grant from the Oak Foundation (OFIL-24-074). The funders had no role in considering the study design or in the collection, analysis, interpretation of data, writing of the report, or decision to submit the article for publication.
- Language
- English
- Date published
- 09/29/2026
- Academic Unit
- Biostatistics
- Record Identifier
- 9985237505302771
Metrics
5 Record Views